Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
May 02 2024 - 8:30AM
Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), today
highlights results from our licensor’s 2022 preclinical studies
evaluating the treatment effect of its recently in-licensed asset,
EL-22. EL-22 will primarily be commercialized by Elevai
Biosciences, Inc., a biopharmaceutical division of the Company
focusing on the development and acquisition of cutting-edge
aesthetic medicines. Based on our licensor’s 2022 preclinical data,
Elevai believes that EL-22 has the potential to treat obesity in
combination with GLP-1 receptor agonists by preserving muscle mass
while decreasing fat mass.
“With the growing prevalence of obesity, and popularity of drugs
like Ozempic and Mounjaro, we believe there is a need for a
treatment option that leads to weight loss without the associated
loss of muscle. Based on the preclinical data generated by our
licensor, we believe that EL-22 has the potential to treat obesity
while supporting and preserving existing muscle,” said Jordan R.
Plews, Ph.D., Chief Executive Officer of Elevai. “EL-22 is an
engineered probiotic expressing myostatin on its surface, which
triggers a mucosal immune response resulting in the body’s own
anti-myostatin antibodies. Myostatin has been shown to play an
important role in regulating muscle and the preclinical data show
potential proof-of-mechanism of EL-22 to preserve muscle fibers in
mouse models of Duchenne muscular dystrophy by reducing the effects
of myostatin.”
Specifically, in the preclinical studies1:
- EL-22 showed a
statistically significant increase in anti-myostatin IgG antibody
concentration, where myostatin is a key negative regulator of
muscle growth.
- Statistically significant decrease in creatine kinase levels,
which indicates a decrease of muscle destruction.
- EL-22 administered to mdx mice, a mouse model of Duchenne
muscular dystrophy, had improved physical activity and gross motor
function, as demonstrated by a longer duration during rotarod
tests.
Based on the highlighted preclinical data, Elevai believes that
EL-22 has the potential to treat obesity in combination with GLP-1
by preserving muscle mass while decreasing fat mass. The Company
intends to complete an IND submission in 2025 and to initiate
clinical trials in the U.S. to evaluate the myostatin approach in
combination with one or more GLP-1 receptor agonists in
obesity.
About Elevai Labs Elevai Labs Inc. (NASDAQ:
ELAB) specializes in medical aesthetics and biopharmaceutical drug
development, focusing on innovations for skin aesthetics and
treatments tied to obesity and metabolic health. Driven by a
commitment to scientific research, we aim to transform personal
health and beauty. For more information, please visit
www.elevailabs.com.
About Elevai Biosciences Elevai Biosciences
Inc., an Elevai Labs company, is a biopharmaceutical company
focusing on the development and acquisition of cutting-edge
aesthetic medicines. Our lead asset, EL-22, is leveraging a
first-in-class engineered probiotic approach to address obesity’s
pressing issue of preserving muscle while on weight loss
treatments, including GLP-1 receptor agonists. For more
information, please visit www.elevaibio.com.
Cautionary Note Regarding Forward-Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Words such as “believes,” “expects,” “plans,”
“potential,” “would” and “future” or similar expressions such as
“look forward” are intended to identify forward-looking statements.
Examples of these forward-looking statements include statements
concerning: Elevai’s expectations regarding its growth, strategy,
progress and the design, objectives and timing of its clinical
trials for EL-22; and the potential of EL-22 to treat obesity
without an associated loss of muscle, both as a monotherapy and in
combination with GLP-1 receptor agonists. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. These risks and uncertainties include, among others:
Elevai’s limited operating history and historical losses; Elevai’s
ability to raise additional funding to complete the development and
any commercialization of its product candidates; Elevai’s
dependence on the success of its product candidates EL-22 and
EL-32; that Elevai may be delayed in initiating, enrolling or
completing any clinical trials; competition from third parties that
are developing products for similar uses; Elevai’s ability to
obtain, maintain and protect its intellectual property; and
Elevai’s dependence on third parties in connection with
manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in Elevai’s
filings with the Securities and Exchange Commission (“SEC”),
including the “Risk Factors” section of the Company’s Annual Report
on Form 10-K for the year ended December 31, 2023, filed with the
SEC on March 29, 2024, and its other documents subsequently filed
with or furnished to the SEC. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Except to the extent required by law, the Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Media & Product Contact:
Brenda Buechler, CMO
contact@elevailabs.com
Investor Relations Contact:
Tyler Troup, Circadian Group IR
IR@elevailabs.com
1 Reference: Sung DK, Kim H, Park SE, Lee J, Kim JA, Park YC,
Jeon HB, Chang JW, Lee J. A New Method of Myostatin Inhibition in
Mice via Oral Administration of Lactobacillus
casei Expressing Modified Myostatin Protein, BLS-M22, Int. J.
Mol. Sci. 2022, 23, 9059.
https://doi.org/10.3390/ijms23169059
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From May 2024 to Jun 2024
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Jun 2023 to Jun 2024